On June 17, Novo Nordisk rose 3.24% in regular trading, trading at $44.905/share, with turnover of $68.62 million. The stock gained momentum following multiple positive catalysts centered on the company's oral weight-loss drug strategy.

Novo Nordisk's global CEO Mike Doustdar announced that the company plans to submit clinical data for oral Wegovy to Chinese regulators within the coming months to seek marketing approval. China represents Novo Nordisk's second-largest market globally after the United States. Doustdar also indicated that the company's BD transactions in China will increase, noting ongoing discussions with multiple Chinese companies. Additionally, oral Wegovy recently received approval from UK regulators, making it the first European market to clear the drug. Clinical trial data showed patients achieved average weight loss of 13.6% after 64 weeks. The CEO further clarified that semaglutide's regulatory data protection in China extends through Q2 2027, delaying generic competition.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)